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Contrary to early views, we now know that systemic inﬂammatory/immune responses
transmit to the brain. The microglia, the resident “macrophages” of the brain’s innate
immune system, are most responsive, and increasing evidence suggests that they enter
a hyper-reactive state in neurodegenerative conditions and aging. As sustained over-
production ofmicroglial pro-inﬂammatorymediators is neurotoxic, this raises great concern
that systemic inﬂammation (that also escalates with aging) exacerbates or possibly trig-
gers, neurological diseases (Alzheimer’s, prion, motoneuron disease). It is known that
inﬂammation has an essential role in the progression of Alzheimer’s disease (AD), since
amyloid-β (Aβ) is able to activatemicroglia, initiating an inﬂammatory response, which could
have different consequences for neuronal survival. On one hand, microglia may delay the
progression of AD by contributing to the clearance of Aβ, since they phagocyte Aβ and
release enzymes responsible for Aβ degradation. Microglia also secrete growth factors
and anti-inﬂammatory cytokines, which are neuroprotective. In addition, microglia removal
of damaged cells is a very important step in the restoration of the normal brain environ-
ment, as if left such cells can become potent inﬂammatory stimuli, resulting in yet further
tissue damage. On the other hand, as we age microglia become steadily less efﬁcient at
these processes, tending to become over-activated in response to stimulation and instigat-
ing too potent a reaction, which may cause neuronal damage in its own right. Therefore, it
is critical to understand the state of activation of microglia in different AD stages to be able
to determine the effect of potential anti-inﬂammatory therapies. We discuss here recent
evidence supporting both the beneﬁcial or detrimental performance of microglia in AD, and
the attempt to ﬁnd molecules/biomarkers for early diagnosis or therapeutic interventions.
Keywords: microglia, amyloid-β, Alzheimer’s disease, inflammation, NSAIDs, annexin A1, immunity
INTRODUCTION
For many years, the central nervous system (CNS) was considered
to be immune privileged, neither susceptible nor contributing to
infection/inﬂammation. It is now evident that CNS infection and
neurological diseases trigger local inﬂammation and consequently
activation of the immune response. In particular, the response to
aggression is driven by the resident immune cells, the microglia
distributed throughout the normal adult brain (Perry and Ander-
sson, 1992; Nimmerjahn et al., 2005). Speciﬁcally, Alzheimer’s
disease (AD) is characterized by an inﬂammatory response to
Amyloid-β (Aβ), inducing the activation of microglia and the
recruitment of astrocytes to the sites where Aβ deposits occur
(Sastre et al., 2006a).
It is nowadays accepted that there is a dynamic microglia
turnover in the brain and that microglia phenotype may change
depending on aging, stage of the disease, and/or the presence of
peripheral inﬂammation. In the brain there are also inﬁltrated
macrophages,which play an essential role in the immune response.
The purpose of this review is ﬁrst, to describe microglia as a
cell of the immune system and the effects of peripheral inﬂam-
mation on their activation. Secondly, our aim is to describe how
this system is altered in a neurodegenerative disease, such as AD.
Therefore, targeting microglia could serve as a potential therapy
to treat AD patients.
MICROGLIA THE INNATE IMMUNITY CELL COMPONENT
ROLE OF MICROGLIA AND MACROPHAGES IN THE BRAIN
– Microglia represent around 10% of the cells in the nervous sys-
tem. Although there are many theories concerning the origin
of microglia, the general consensus today is its hematopoietic
origin, derived from myeloid precursor cells, which enter the
developingCNS during embryogenesis.Many questions remain
about the recruitment and the life of the resident microglial in
adult and aging brain (Chan et al., 2007).
Microglia constitute the ﬁrst line of defense against invading
pathogens or other types of brain tissue injury. The general
agreement is that microglia are the “sentinels” of the CNS.
Their fundamental role is sensing both pathogen- and host-
derived ligands within the CNS. By detecting the type of insult
and consequently directing the innate to the adaptive immune
response (e.g., removal of pathogen) they are fundamental to
the resolution of inﬂammation. Under pathological situations,
such as neurodegenerative disease, stroke, and tumor invasion,
microglia become activated, surround damaged and dead cells,
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and clear cellular debris from the area, in analogy to phagocytic
macrophages of the immune system (Fetler and Amigorena,
2005). This process plays a fundamental part in the reorga-
nization of neural circuitry and repair mechanisms that arise
following injury (Neumann et al., 2009; Neher et al., 2011).
As part of a beneﬁcial role microglial phagocytosis is a highly
regulated process, with activated microglia expressing a wide,
and redundant, variety of distinct receptors for the removal of
pathogenic organisms, e.g., Toll-like receptors (TLRs;Neumann
et al., 2009), or of apoptotic cell debris, e.g., CD36 and integrins
(Napoli and Neumann, 2009; Lue et al., 2010). The microglial
phagocytic response is thus a central part of the brain’s defense
mechanisms, and is a powerful contributor to the systems in
place that ensure healthy neural function.
Activatedmicroglia also up-regulate other cell-surface recep-
tors, including the major histocompatibility complex and com-
plement receptors (Liu and Hong, 2003). Microglia experi-
ence dramatic morphological changes from ramiﬁed cells to
activated amoeboid microglia (Kreutzberg, 1996). In addition,
when microglia become activated they generate inﬂammatory
mediators like cytokines, chemokines, prostaglandins, inducible
nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), free
radicals, and stimulating an adaptive immune response (Nim-
merjahn et al., 2005; Ransohoff and Perry, 2009). The principal
goals of such reactions include the repair and the restoration
of the homeostasis, but complications often arise, resulting in
detrimental effects and actual exacerbation of the occurring
damage (Lehnardt, 2010).
– Apart from resident microglia, in the brain there are monocyte-
derived macrophages (Schwartz and Shechter, 2010). Perivas-
cular macrophages have a phagocytic role and are also impli-
cated in the presentation of antigens to T cells that have been
activated in the periphery, thereby facilitating the recognition
of CNS antigens (Perry et al., 2010). The macrophage and
microglia phenotype has been deﬁned as M1 (classically acti-
vated via TLRs or interferon γ) and M2 (alternatively activated
by interleukin 4 or interleukin 13), although it is assumed that
a mixed population of both phenotypes exists (Cameron and
Landreth, 2010; Perry et al., 2010). Because most techniques are
unable to differentiate between both populations of microglia
and macrophages in the brain, they are collectively referred as
microglia. However, both microglia and inﬁltrated monocytes
are not functionally redundant and have different properties, so
they are both necessary to display functions such as brain repair.
IMPACT OF PERIPHERAL INFLAMMATION IN THE BRAIN
Inﬂammation is a response mounted by the innate immune sys-
tem in response to injury and infections in order to promote
recovery. It was long thought that the brain was protected from
systemic inﬂammation. However, growing evidence shows that
systemic inﬂammatory stimuli, such as infection, also trigger a
central response through microglia with consequent release of
pro-inﬂammatory mediators (cytokines, lipid metabolites, free
radicals). As part of the host-defense process, this stimulates
autonomic, neuroendocrine, and behavioral responses that pro-
mote recovery. Under normal conditions the neuroinﬂammatory
response resolves and microglia resume their “resting” state and
role of monitoring the microenvironment. However, increasing
experimental and clinical evidence indicates that systemic inﬂam-
mation can worsen, or possibly trigger, neurological diseases
(Weller et al., 2005; Ransohoff and Perry, 2009). These include
stroke (McColl et al., 2007), Alzheimer’s, prion, and motoneuron
diseases (Nguyen et al., 2004; Perry, 2004; Rogers et al., 2007).
Although the underlying mechanisms are not clear, mounting
evidence suggests that microglia enter a primed/hyper-sensitive
state in neurodegenerative conditions. This pre-disposes to an
exaggerated production of toxic pro-inﬂammatory mediators in
response to systemic inﬂammogens, thereby exacerbating neu-
ronal loss (Streit et al., 2004; Godbout et al., 2005; Perry et al.,
2007).
Understanding the routes of communication between periph-
eral immune responses and the brain has not been an easy chal-
lenge (Perry et al., 2007). The general belief is that immune
messages are passed to the brain mainly through three differ-
ent pathways: ﬁrst, peripherally derived signals (mainly pro-
inﬂammatory cytokines like IL-1β, TNF-α, and IL-6) and even
pathogen-associated molecular patterns (PAMPs; for example the
lipopolysaccharide (LPS), the main cell-wall component of Gram-
negative bacteria) can access the nervous system through brain
sites that lack a proper blood brain barrier (BBB), or through
fenestrated capillaries (Rivest, 2003); secondly, on-going periph-
eral reactions can be sensed and transmitted to the brain via
neural afferent pathways, mainly through the vagus nerve (Gao
et al., 2008); lastly, the BBB itself, through the role of its numer-
ous cellular components like endothelial cells and perivascular
macrophages can sense circulating signals and respond to them,
affecting behavior of neurons, astrocytes, and especially resident
microglia population (Rivest, 2009; Figure 1).
MICROGLIA IN AGING
Despite the similarities with the innate immune response in the
peripheral system, there are important differences with brain envi-
ronment, where the microglia activity could be sometimes delete-
rious for the brain. This in-balance phenotype is determined by
the fact that neuroinﬂammation may be chronic or acute (Colton,
2009). Both chronic low-grade peripheral inﬂammation (Ouchi
et al., 2005) and microglial priming/hypersensitivity are associated
with aging.
It is well known that microglia exhibit signiﬁcant phenotypic
changes during normal aging. Microglia cells from both aged
humans and rodents show profoundly altered morphology, char-
acterized by dystrophic processes, and abnormal clustering (Perry
et al., 1996; Streit et al., 2008). These changes in morphology are
accompanied by increased expression of activation markers such
as MHCII and RAGE (Perry et al., 1993), raised basal production
of the pro-inﬂammatory cytokines TNFα, IL-6, and IL-1β (Ye and
Johnson, 1999; Xie et al., 2003; Sierra et al., 2007), and hyper-
responsiveness to inﬂammatory stimulation (Njie et al., 2012),
together suggesting that microglia become progressively dysfunc-
tional with age. A likely explanation for this fact lies in the loss
of endogenous factors which would normally control/drive pre-
vent excessive microglial activation, and promote the beneﬁcial,
anti-inﬂammatory, phenotype. We could further hypothesize that
microglia turnover with aging is reduced and that newly attracted
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FIGURE 1 | Peripheral infection/inflammation causes the release of
pro-inflammatory mediators, including cytokines (TNF-α, IL-1β, IL-6),
arachidonic acid (AA), prostaglandins (PGs), and nitric oxide (NO)
synthesis.The brain also mounts an inﬂammatory response to systemic
inﬂammation, as well as to local injury (neurodegeneration, trauma, stroke),
with the microglial cells responding soonest and with production of the
greatest amounts of pro-inﬂammatory mediators. However, the central
response appears to be under tighter control than the peripheral response
in that it is delayed and more modest, probably in order to avoid the dire
consequences of a full-blown inﬂammatory response within the conﬁnes of
the skull. Modiﬁed after Solito et al. (2008).
monistic cells may acquire a wrong phenotype once enriched the
brain environment (Koﬂer and Wiley, 2011).
In summary, microglial activation presents a double-edged
sword: from one side we can deﬁne it as neuroprotective, forming
the ﬁrst line of defense in the CNS; from the other, it can become a
neurodegenerative force, when its power is excessive and to repre-
sent risk factors for developing age-associated neurodegenerative
disease (AD), contributing to the worsening of symptoms that
occur after systemic infection (Perry et al., 2007). Understand-
ing the shift between these two opposite and the changes that
occurring with aging will allow us to minimize the harmful and
capitalize the beneﬁcial effects and consequently the treatment of
neurodegenerative diseases (Yong and Rivest, 2009).
MICROGLIA IN ALZHEIMER’S DISEASE
IMPLICATIONS OF AD PATHOGENESIS IN MICROGLIA ACTIVATION
Inﬂammation has been implicated in neuronal damage, increased
Aβ generation, increased phosphorylation of tau, and cognitive
impairment in AD. Cause or consequence of disease progres-
sion is still not clear. Clinical work and studies in animal models
suggest that microglial activation precede amyloid plaques and
tangles formation (Grifﬁn et al., 1989; Heneka et al., 2005a) while
PET studies have reported inﬂammatory changes in one-third of
amnestic mild cognitive impairment (MCI; Cagnin et al., 2001;
Okello et al., 2009).
Many of the cytokines and chemokines secreted by microglia
such as IL-1β, IL-6, TNF-α, IL-8, TGF-β, and macrophage inﬂam-
matory protein-1α (MIP-1α) have been found to have altered
expression in AD patients compared to control individuals (Sastre
et al., 2006a). Animal models of AD, including the APP trans-
genic line Tg2567 carrying the Swedish mutation, also show ele-
vated levels for TNF-α, IL-1β, IL-1α, chemoattractant protein-1,
COX-2, and complement component 1q (Benzing et al., 2000;
Matsuoka et al., 2001). In addition, an increased risk of AD has
been associated with several polymorphisms of pro-inﬂammatory
genes, including IL-1 (Nicoll et al., 2000), IL-6 (Capurso et al.,
2004), TNF-α (McCusker et al., 2001; Perry et al., 2001), and
α1-antichymotrypsin (Kamboh et al., 1995).
Amyloid peptides and their precursor protein (APP) are strong
glial activators (Barger and Harmon, 1997) and knockdown
of APP gene and its proteolytic products delay and decrease
microglial activation (DeGiorgio et al., 2002). The extent of astro-
cytosis and microglial activation is directly dependent on the
amyloid load, and treatment with β-sheet breaker peptides leads to
reduced brain inﬂammation (Permanne et al., 2002). Aβ is able to
activate a NFκB-dependent pathway that is required for cytokine
production (Combs et al., 2001). In addition, the C-terminal (CT)
100 amino acids of βAPP, which is also present in senile plaques,
can induce gliosis and neuronal death. CT100 exposure results in
activation of mitogen-activated protein kinase (MAPK) pathways
as well as NFκB (Bach et al., 2001). At the same time, inﬂammation
may increase Aβ generation by affecting the transcription of the
β-secretase (BACE1), the main enzyme responsible for Aβ genera-
tion (Sastre et al., 2006b, 2008), therefore creating a feed-forward
cycle.
In addition, neuroinﬂammation participates in tau-mediated
neurodegeneration (Jaworski et al., 2011). Animal models of
tauopathy such as the P301S tau transgenic mice exhibit accumu-
lation of activated microglial cells around tau-positive nerve cells
(Yoshiyama et al., 2007). Eventually, pro-inﬂammatory cytokines
are also able to modify the activity of kinases involved in Tau phos-
phorylation (Arnaud et al., 2006). Products of inﬂammationmight
change the substrate speciﬁcity of kinases/phosphatases leading to
tau phosphorylation at pathological sites. It was shown recently
that inﬂammation induced by infection increased GSK3 activity
in the triple-transgenic mouse model of AD, associated with a
shift of tau from the detergent-soluble to the detergent-insoluble
fraction (Sy et al., 2011).
On the other hand, other proteins involved in AD, such
as presenilin, have been implicated in inﬂammation. Presenilin
conditional knockout mice present differential up-regulation of
inﬂammatory markers in the cerebral cortex, such as strong
microglial activation, and elevated levels of glial ﬁbrillary acidic
protein (GFAP), complement component C1q, and cathepsin S
(Beglopoulos et al., 2004). In fact, γ-secretase inhibitors have been
reported to impair microglial activity as measured in gene expres-
sion, protein levels, and migration ability, which resulted in a
reduction of soluble β-amyloid phagocytosis. Moreover,microglia
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deﬁcient in presenilin 1 and 2 showed impairment in phagocytosis
of soluble β-amyloid (Farfara et al., 2011).
MECHANISMS OF Aβ-INDUCED MICROGLIAL ACTIVATION
As indicated above, Aβ is able to bind and activate microglia. The
mechanism of action for this is through interaction with pat-
tern recognition receptors (PRRS). Microglia express many PRRs
(Farina et al., 2007; Falsig et al., 2008),which recognize and bind to
both PAMPs, or danger-associated molecular patterns (DAMPs),
such as Aβ (Salminen et al., 2009). Interaction of microglia with
Aβ, via PRRs provokes their inﬂammatory actions.
Toll-like receptors
Toll-like receptors are a type-1 integral glycoproteins (Pancer and
Cooper, 2006; Miyake, 2007). Among the cell-surface TLRs, TLR2
and 4 can recognize Aβ (Carty and Bowie, 2011). Several studies
have conﬁrmed that TLR4 mediates microglial-induced neurotox-
icity both in vivo and in vitro (Lehnardt et al., 2003; Walter et al.,
2007).
Toll-like receptor activation is regulated by co-receptors,
includingMD-2,CD14,andCD36 (Akashi-Takamura andMiyake,
2006). Research using knockout mice for TLR4 or TLR2 demon-
strated an increase in Aβ deposition and acceleration in cognitive
decline (Tahara et al., 2006; Richard et al., 2008). These results sug-
gest that TLR2 and TLR4 may be involved in Aβ clearance in vivo
and hence provide neuroprotection in AD. In fact, it was shown
that response of microglial cells to ﬁbrillar forms of Aβ requires the
participation of TLRs and the co-receptor CD14 (Reed-Geaghan
et al., 2009). However, microglia internalize soluble Aβ through
a non-saturable, ﬂuid phase macropinocytic mechanism that is
distinct from phagocytosis and receptor-mediated endocytosis
(Mandrekar et al., 2009).
Receptor for advanced end glycation products (RAGE)
RAGE is a member of the immunoglobulin superfamily of cell-
surface proteins (Schmidt et al., 2001; Chavakis et al., 2003; Bier-
haus et al., 2005). It is a multiligand receptor, which recognizes
Aβ peptides and ﬁbrils (Knapp and Prince, 2007). Interestingly,
RAGE-expressing microglia are upregulated in AD, and microglial
RAGE is reported to mediate the pro-inﬂammatory effects of Aβ
(Yan et al., 1996; Lue et al., 2001; Arancio et al., 2004). This is sup-
ported by recent work whereby it was demonstrated in transgenic
AD models that the interaction of microglial RAGE with Aβ acti-
vates signal transduction cascades (MAPkinase,p38,andERK1/2),
enhances cytokines production (IL-β and TNF-α), and accelerates
or ampliﬁes the inﬂammatory response, leading to recruitment or
activation of microglia and astrocytes (Fang et al., 2010).
Scavenger receptors
Scavenger receptor (SR) type-A (SR-A), type B1 (SR-B1), CD36,
and CD40 are established receptors for insoluble ﬁbrillar Aβ
aggregates, and are expressed by activated microglia, mediating
the endocytosis of oligomeric and ﬁbrillar Aβ (El Khoury et al.,
1996; Paresce et al., 1996; Coraci et al., 2002; Husemann et al.,
2002). Microglial adherence via SR-A binding to ﬁbrillar Aβ leads
to microglial immobilization, production of ROS, secretion of
cytokines such as TNF-α and complement proteins (El Khoury
et al., 1996).
Formyl peptide receptors
Aβ can also bind to members of the seven-transmembrane G pro-
tein coupled receptors known as formyl peptide receptors (FPRs;
Le et al., 2002). FPR, FPR-like 1 (FPRL-1), and FPR-like 2 (FPRL2)
have been characterized as series of receptors, for which the main
endogenous ligand is Annexin A1 (ANXA1; Solito et al., 2008).
These receptors bind with high afﬁnity to N-formylated bacterial
peptides. FPRs are expressed on several immune cells including
leukocytes, monocytes, and microglia. Among them the FPRL-
1 mediates the chemotactic activity of Aβ42 for mononuclear
phagocytes and therefore appear to be pathophysiologically rel-
evant in the AD (Iribarren et al., 2005). In addition, Aβ bound to
FPRL-1 is rapidly internalized into the cytoplasmic region as lig-
and/receptor complexes in mononuclear phagocytes. This process
may represent responses of host-defense aiming at the clearance
of abnormally elevated, pathogenic Aβ. However, the Aβ interac-
tion with FPRL-1 is clearly associated with cell activation (Cui
et al., 2002) and the release of pro-inﬂammatory and neuro-
toxic mediators (Pan et al., 2011). Interestingly FPRL-1 is highly
express in mononuclear phagocytes surrounding and inﬁltrating
Congo red-positive plaques in AD patients’ brain tissue (Le et al.,
2001).
Complement receptors
Complement receptors are one of the categories of cell-surface
molecules on microglia that are upregulated in response to the
activationof these cells (Liu andHong,2003).Aβ-induced comple-
ment activation leads to generation of C1q, C4, and C3 activation
fragments around the plaques. Here microglia express comple-
ment proteins C1q, C3, and receptors C1qR, CR3, CR4, and C5aR,
which support phagocytic uptake (Keene et al., 2011). Inhibition
of the complement system results in an increase of Aβ plaque for-
mation and neurodegeneration in AD transgenic mice (Shen and
Meri, 2003).
In contrast, lack of C1q inmicemodels of AD results in decrease
pathology (Hafer-Macko et al., 2000). This indicates that one
mechanism by which microglia could recruit further reactive cells
to the site of a plaque and cause neurotoxic damage is by activating
the classic complement pathway and the inﬂammatory machinery
associated with it (pro-inﬂammatory cytokines, oxidative prod-
ucts) through production of C1q (McGeer and McGeer, 1998;
Bonifati and Kishore, 2007).
The demonstration that the peripheral benzodiazepine recep-
tor is upregulated in activated microglia led to the development
of a ligand, [11C](R)-PK11195, which binds to this receptor also
known as the 18-kDa translocator protein (TSPO). Extensive amy-
loid deposition and microglial activation can be demonstrated in
the same group of AD patients in vivo by PET using [11C]PK11195
and a negative correlation between microglial activation and lev-
els of cognition has been reported. Both amyloid deposition
and microglial activation can be detected in vivo with PET in
around 50% of patients with MCI. However, amyloid deposition
and microglial activation are not necessarily correlated in MCI
suggesting both can occur in the absence of the other (Okello
et al., 2009; Sastre et al., 2011). On the other hand, a signiﬁcant
age-dependent increase in speciﬁc [3H](R)-PK11195 binding was
also demonstrated in a transgenic mouse model of AD (TASTPM:
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APPswxPS1M146V; Roberts et al., 2009). This was consistent with
immunohistochemical data showing age-dependent increases in
CD68 immunoreactivity co-localized with Aβ deposits. CD68
is a 110-kDa transmembrane glycoprotein, expressed by mono-
cyte/macrophage lineages and serves as a marker for microglia.
Interestingly, an antibody to human TSPO revealed induction
of TSPO-positive microgliosis by tau ﬁbrils in tauopathy brains.
In addition, in transgenic PS19 mice, carrying the P301S Tau
mutation, radiolabeling of TSPO with [11C]AC-5216 was lin-
early proportional to the amount of phospho-tau immunolabeling
(Maeda et al., 2011). The results of that study indicated that TSPO
immunoreactivities are associated with NFTs, neuropil threads,
andplaque neuritis rather thanAβdeposits.All together, the analy-
sis of microglia by PET in AD and MCI patients plus the studies
of microglial activation over time in animal models suggest that
microglia activation occurs before Aβ deposition and correlates
better with cognitive deﬁcits and tau phosphorylation.
MICROGLIAL ACTIVATION IN DIFFERENT STAGES OF AD
It has been hypothesized that early microglial activation in AD
delays disease progression by promoting clearance of Aβ before
formation of senile plaques. It is conceivable that glial activa-
tion is protective early in the disease (Wyss-Coray et al., 2003;
Maragakis and Rothstein, 2006; Wyss-Coray, 2006). In fact, stud-
ies have shown that blood derived macrophages (BMDM) are able
to efﬁciently eliminate amyloid and confer neuroprotection by
secretion of growth factors such as the glia-derived neurotrophic
factor (GDNF), which are potentially beneﬁcial to the survival of
neurons (Liu and Hong, 2003). Activated microglia in early stages
of AD can reduce Aβ accumulation by increasing its phagocyto-
sis, clearance, and degradation (Frautschy et al., 1998; Qiu et al.,
1998). The mechanism by which Aβ is phagocytosed depends on
the physical properties of Aβ and whether it is soluble or ﬁbrillar.
Secreted Aβ1-40 and Aβ1-42 peptides are constitutively degraded
by neprilysin and the insulin degrading enzyme (IDE), a met-
alloprotease released by microglia and other neural cells, whose
enzymatic activity is enhanced by inﬂammatory events, such as
LPS stimulation (Qiu et al., 1997).
In later stages, with persistent production of pro-inﬂammatory
cytokines, microglia lose their protective effect (Hickman et al.,
2008; Jimenez et al., 2008) and may become detrimental through
the release of cytokines and chemokines (Hickman et al., 2008).
These inﬂammatory mediators modulate immune and inﬂam-
matory function and may also alter neuronal function. In addi-
tion, microglia from old transgenic mice have a decrease in the
expression of the Aβ-binding SR-A, CD36 and RAGE, and the
Aβ degrading enzymes IDE, neprilysin, and matrix metallopro-
tease 9 (MMP9), compared with wild-type controls (Hickman
et al., 2008). Therefore, all the evidences support the idea that
over-activated microglia could cause uncontrolled inﬂammation
that may drive the chronic progression of AD by exacerbating
Aβ deposition and stimulating neuronal death (Mrak and Grif-
ﬁn, 2005; Gao and Hong, 2008). This concept constitutes the
“Neuroinﬂammatory hypothesis.”
By comparison, the “Microglial dysfunction hypothesis” stipu-
lates that rather than an increase of inﬂammatory function there
is a loss of the microglial neuroprotective function in AD (Polazzi
and Monti, 2010). Research has shown that the phagocytic abilities
of microglia are altered in aging and impaired in neurodegener-
ative diseases. Therefore this “senescent” or dystrophic microglia
can also contribute to the onset of sporadic AD (Streit et al., 2004,
2009).
In addition, other studies have shown that inadequate recruit-
ment of blood monocytes with aging might be a critical event
that leads to disease onset. Because the dynamics of the local
and systemic inﬂammatory response may vary with aging and
stage of the disease, this would important for the outcome of
immunosuppressive treatments (Schwartz and Shechter, 2010).
Studies with animal models have provided controversial data
regarding the role of microglia in AD. Experiments crossing APP
animal models with Iba1-TK mice, leading to nearly complete
ablation of microglia, did not display differences in plaque forma-
tion (Grathwohl et al., 2009). These results suggest that microglia
may not have a direct role on Aβ deposition, but affect neuronal
function. These results also reinforce the role of blood monocytes,
whichmay support thephagocytic functionof microglia.However,
another study, using two-photon microscopy, performed in triple-
transgenic mice crossed with the microglial chemokine receptor
CX3CR1 knockout mouse, revealed that microglia is involved in
neuron elimination, indicated by locally increased number and
migration velocity of microglia around lost neurons (Fuhrmann
et al., 2010). Microglia were recruited to the neuron before and
not after the elimination of the neuron. Furthermore, CX3CR1
knockout prevented neuronal loss, indicating that neuronal loss
depends on the communication between neurons and microglia
(Fuhrmann et al., 2010).
MICROGLIA AS TARGET FOR AD THERAPY
Anti-inﬂammatory drugs
Microglia associated with the senile plaques is thought to be
a potential target of non-steroidal anti-inﬂammatory drugs
(NSAIDs). A study by Mackenzie and Muñoz (1998) carried out
in non-demented patients showed that those treated with NSAIDs
had three times less activated microglia as non-treated controls.
These data have been conﬁrmed by in vivo treatment with NSAIDs
such as ibuprofen in mouse models of AD, which have shown
decreases in microglial activation and in inﬂammatory media-
tors such as iNOS, cyclooxygenase (COX), and cytokines (Lim
et al., 2000; Heneka et al., 2005b). Experiments performed using
cultured microglia have revealed that incubation with NSAIDs
decreased the secretion of pro-inﬂammatory cytokines and may
increase Aβ phagocytosis (Lleo et al., 2007). However, the reduc-
tion of activated microglia and astroglia by NSAIDs was not
signiﬁcant in AD patients, indicating an age or stage dependent
difference in the glial response, i.e., in their activation rate (Alafu-
zoff et al., 2000). Microglia in aged or diseased brains are primed
andusually behave differently to those in younger individuals (Gao
and Hong, 2008). Thus, it is likely that microglia do not respond
equally to anti-inﬂammatory therapy in old age and therefore,
treatment of patients with NSAIDs in advanced stages of the dis-
ease may not produce any beneﬁt. In this regard, NSAIDs have
been shown to have beneﬁcial effects in young individuals with
robust immune systems. In aged patients, these drugs may affect
the weak systemic immune response of the patients, exacerbating
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the local damage by eliminating the capacity of the immune sys-
tem to introduce disease-modifying factors to the inﬂamed area
(Sastre and Gentleman, 2010) (Figure 2).
A potential downstream target of someNSAIDs such as ibupro-
fen, indomethacin, and naproxen is the peroxisome proliferator-
activated receptor-γ (PPAR-γ; Lehmann et al., 1997;Willson et al.,
2000). Several PPAR-γ activators including NSAIDs, drugs of the
thiazolidinedione class, and the natural ligand prostaglandin J2
(15d-PGJ2) have been shown to be able to inhibit the β-amyloid-
stimulated secretion of pro-inﬂammatory products by microglia
and monocytes responsible for neurotoxicity and astrocyte acti-
vation (Combs et al., 2000). Furthermore 15d-PGJ(2) caused
microglial death,which terminates brain inﬂammation (Yang et al.,
2006).
Interestingly, anti-TNFα treatment reduced Aβ and Tau phos-
phorylation in transgenic mice. Treatment with the antibody
againstTNF-α Inﬂiximab increased thenumber of CD11c-positive
dendritic-like cells and the expression of CD11c. These data
suggested that the CD11c-positive dendritic-like cells might con-
tribute to the Inﬂiximab-induced reduction of AD-like pathology
(Shi et al., 2011).
Therapeutic vaccination with Aβ antibodies in mice evidenced
the Fc-mediated uptake and clearance of Aβ antibody complexes
by local activated microglia (Bard et al., 2000; Weiner and Selkoe,
2002). Therefore, it was proposed that microglial activation by
active immunization might be a valid mechanism for clearance of
senile plaques (Gelinas et al., 2004).
Endogenous molecule for the control of microglia detrimental action
The major breakthrough in the therapy of neurodegenerative
disease would be controlling the switch between the beneﬁcial
versus the detrimental microglia phenotype in order to control
inﬂammation.
Because Aβ stimulates microglia phagocytosis with consequent
release of toxic factors,many studies have reported possible mech-
anism of action implicating receptors on microglia surface. In this
regard, therapeutic agents that are able to disrupt the interaction
between Aβ42 and FPR may prove beneﬁcial in the treatment
of AD.
We have recently published data providing strong indication
for a protective role of a protein called annexin A1 (ANXA1),
a glucocorticoid anti-inﬂammatory mediator in the peripheral
system (Perretti and D’Acquisto, 2009). ANXA1 plays a key
role in ensuring the effective and selective removal of apoptotic
neuron-like cells under inﬂammatory andnon-inﬂammatory con-
ditions which is a ligand for FPRL-1 receptor (McArthur et al.,
2010).
Our studies have shown that ANXA1 is upregulated in human
microglia in AD, supporting a possible role for the protein in
regulating the microglial response to amyloid plaques and inﬂam-
matory response in neurodegeneration. This view is strongly
supported by further ﬁndings in which recombinant ANXA1
administration in vitro suppress microglial activation following
an inﬂammatory challenge (McArthur et al., 2010).
The identiﬁcation of microglial FPRL-1 as a receptor for
ANXA1, together with our identiﬁcation of strong expression
of ANXA1 in neuritic plaque-associated microglia in AD, sug-
gests a fascinating connection with published data indicating a
link between Aβ and FPRL-1 (Heurtaux et al., 2010). Microglia
have clearly been shown to phagocytose Aβ through this receptor,
but they appear unable to digest this protein, leading to persis-
tent internalization of Aβ/FPRL-1 complexes and culminating in
intracellular ﬁbril formation and apoptosis (Pan et al., 2011). The
binding of ANXA1 to FPRL-1 in microglia may thus be able to
disrupt the interaction of the receptor with Aβ, potentially being
of signiﬁcant beneﬁt in the treatment of AD (Figure 3).
CONCLUSION
Microglia effects on AD seem to have double component. On one
hand their activation seems to be neuroprotective at early stages
of the disease but at older ages and in severely ill patients the
effects could be counterproductive. There is therefore the need
FIGURE 2 | Different effects of NSAIDs on microglia.The
response to NSAIDs may differ depending on whether they are
used in early stages of disease, in which microglia present an
alternatively activated phenotype compared with late stages which
is associated with a classical microglia phenotype. (Adapted from
Sastre and Gentleman, 2010). Abbreviations: ROS, reactive oxygen
species; NOS2, same as iNOS; IDE, insulin degrading enzyme; SC,
scavenger receptors.
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FIGURE 3 | Hypothetical annexin A1- FPRLI mechanism of action in
microglia. Annexin A1 binds to FPRL-1 triggering an SOS signaling limiting
microglia response to Aβ and preventing a constant uptake and apoptosis,
altering microglia pro-inﬂammatory phenotype.
to investigate the changes in phenotype of resident microglia
and how they react to anti-inﬂammatory therapy over age. In
addition, it would be relevant to determine the role of monocyte-
derived macrophages along different stages of the disease. One
could speculate that the use of BMDM, which are more effec-
tive at degrading Aβ could compensate the defective functions of
senescent resident microglia (Davoust et al., 2008).
In the future, the combineduse of amyloid andmicroglial imag-
ing should allow one to determine how different anti-amyloid
strategies exert their therapeutic effects. Follow-up and further
imaging of patients at risk of developingAD with radiotracers that
bind to the TSPO/peripheral benzodiazepine receptor will enable
a better understanding of both the pattern and the time course
of microglial activation and will also provide the opportunity
to monitor the pathophysiological effects of anti-inﬂammatory
agents in these patients in vivo.
ACKNOWLEDGMENTS
Wewould like to thank Prof. GlendaGillies (Imperial College Lon-
don) for critical reading of the manuscript and the Alzheimer’s
Research UK for their support. We also thank The Wellcome
Trust.
REFERENCES
Akashi-Takamura, S., and Miyake, K.
(2006). Toll-like receptors (TLRs)
and immune disorders. J. Infect.
Chemother. 12, 233–240.
Alafuzoff, I., Overmyer, M., Helisalmi,
S., and Soininen, H. (2000).
Lower counts of astroglia and
activated microglia in patients with
Alzheimer’s disease with regular use
of nonsteroidal anti-inﬂammatory
drugs. J. Alzheimers Dis. 2,
37–46.
Arancio, O., Zhang, H. P., Chen, X., Lin,
C., Trinchese, F., Puzzo, D., Liu, S.,
Hegde,A.,Yan, S. F., Stern,A., Luddy,
J. S., Lue, L. F., Walker, D. G., Roher,
A., Buttini, M., Mucke, L., Li, W.,
Schmidt, A. M., Kindy, M., Hyslop,
P. A., Stern, D. M., and Du Yan, S.
S. (2004). RAGE potentiates Abeta-
induced perturbation of neuronal
function in transgenic mice. EMBO
J. 23, 4096–4105.
Arnaud, L., Robakis, N. K., and
Figueiredo-Pereira, M. E. (2006). It
may take inﬂammation, phospho-
rylation and ubiquitination to ‘tan-
gle’ in Alzheimer’s disease. Neurode-
gener. Dis. 3, 313–319.
Bach, J. H., Chae, H. S., Rah, J. C., Lee,
M. W., Park, C. H., Choi, S. H., Choi,
J. K., Lee, S. H., Kim, Y. S., Kim,
K. Y., Lee, W. B., Suh, Y. H., and
Kim, S. S. (2001). C-terminal frag-
ment of amyloid precursor protein
induces astrocytosis. J. Neurochem.
78, 109–120.
Bard, F.,Cannon,C., Barbour,R., Burke,
R. L., Games, D., Grajeda, H., Guido,
T.,Hu,K.,Huang, J., Johnson-Wood,
K., Khan, K., Kholodenko, D.,
Lee, M., Lieberburg, I., Motter, R.,
Nguyen, M., Soriano, F., Vasquez,
N., Weiss, K., Welch, B., Seubert, P.,
Schenk, D., and Yednock, T. (2000).
Peripherally administered antibod-
ies against amyloid beta-peptide
enter the central nervous system and
reduce pathology in a mouse model
of Alzheimer disease. Nat. Med. 6,
916–919.
Barger, S.W., andHarmon,A.D. (1997).
Microglial activation by Alzheimer
amyloid precursor protein andmod-
ulation by apolipoprotein E. Nature
388, 878–881.
Beglopoulos, V., Sun, X., Saura, C. A.,
Lemere, C. A., Kim, R. D., and Shen,
J. (2004). Reduced b-amyloid pro-
duction and increased inﬂammatory
responses in presenilin conditional
knock-out mice. J. Biol. Chem. 279,
46907–46914.
Benzing,W. C.,Wujek, J. R.,Ward, E. K.,
Shaffer, D., Ashe, K. H., Younkin, S.
G., and Brunden, K. R. (2000). Evi-
dence for glial-mediated inﬂamma-
tion in aged APPSw transgenic mice.
Neurobiol. Aging 16, 523–530.
Bierhaus, A., Humpert, P. M., Morcos,
M., Wendt, T., Chavakis, T., Arnold,
B., Stern, D. M., and Nawroth, P.
P. (2005). Understanding RAGE, the
receptor for advanced glycation end
products. J. Mol. Med. (Berl.) 83,
876–886.
Bonifati, D. M., and Kishore, U.
(2007). Role of complement in
neurodegeneration and neuroin-
ﬂammation. Mol. Immunol. 44,
999–1010.
Cagnin, A., Brooks, D. J., Kennedy,
A. M., Gunn, R. N., Myers,
R., Turkheimer, F. E., Jones,
T., and Banati, R. B. (2001).
In-vivo measurement of activated
microglia in dementia. Lancet 358,
461–467.
Cameron, B., and Landreth, G. E.
(2010). Inﬂammation, microglia,
and Alzheimer’s disease. Neurobiol.
Dis. 37, 503–509.
Capurso, C., Solfrizzi, V., D’Introno,
A., Colacicco, A. M., Capurso,
S. A;.,Capurso, A., and Panza, F.
(2004). Interleukin 6-174 G/C pro-
moter gene polymorphism and
sporadic Alzheimer’s disease: geo-
graphic allele and genotype varia-
tions in Europe. Exp. Gerontol. 39,
1567–1573.
Carty,M., andBowie,A.G. (2011). Eval-
uating the role of Toll-like recep-
tors in diseases of the central ner-
vous system. Biochem. Pharmacol.
81, 825–837.
Chan, W. Y., Kohsaka, S., and Rezaie, P.
(2007). The origin, and cell lineage
of microglia: new concepts. Brain
Res. Rev. 53, 344–354.
Chavakis, T., Bierhaus, A., Al-Fakhri,
N., Schneider, D., Witte, S., Linn, T.,
Nagashima, M., Morser, J., Arnold,
B., Preissner, K. T., and Nawroth,
P. P. (2003). The pattern recogni-
tion receptor (RAGE) is a coun-
terreceptor for leukocyte integrins:
a novel pathway for inﬂammatory
cell recruitment. J. Exp. Med. 198,
1507–1515.
Colton, C. A. (2009). Heterogene-
ity of microglial activation in the
innate immune response in the
brain. J. Neuroimmune Pharmacol. 4,
399–418.
Combs, C. K., Johnson, D. E., Karlo, J.
C., Cannady, S. B., and Landreth,
G. E. (2000). Inﬂammatory
mechanisms in Alzheimer’s disease:
inhibition of b-amyloid stimulated
proinﬂammatory responses and
neurotoxicity by PPARg agonists. J.
Neurosci. 20, 558–567.
Combs, C. K., Karlo, J. C., Kao, S.
C., and Landreth, G. E. (2001). b-
Amyloid stimulation of microglia
and monocytes results in TNFa-
dependent expression of inducible
nitric oxide synthase and neu-
ronal apoptosis. J. Neurosci. 21,
1179–1188.
Coraci, I. S., Husemann, J., Berman, J.
W., Hulette, C., Dufour, J. H., Cam-
panella, G. K., Luster, A. D., Silver-
stein, S. C., and El-Khoury, J. B.
(2002). CD36, a class B scavenger
receptor, is expressed on microglia
in Alzheimer’s disease brains and
can mediate production of reactive
oxygen species in response to beta-
amyloid ﬁbrils. Am. J. Pathol. 160,
101–112.
Cui, Y., Le, Y., Yazawa, H., Gong,W., and
Wang, J. M. (2002). Potential role
of the formyl peptide receptor-like 1
(FPRL1) in inﬂammatory aspects of
Alzheimer’s disease. J. Leukoc. Biol.
72, 628–635.
Davoust, N., Vuaillat, C., Androdias,
G., and Nataf, S. (2008). From
bone marrow to microglia: barriers
and avenues. Trends Immunol. 29,
227–234.
DeGiorgio, L. A., Shimizu, Y., Chun, H.
S., Kim, Y. S., Sugama, S., Son, J. H.,
Joh, T. H., and Volpe, B. T. (2002).
Amyloid precursor protein gene dis-
ruption attenuates degeneration of
substantia nigra compacta neurons
following axotomy. Brain Res. 938,
38–44.
www.frontiersin.org February 2012 | Volume 3 | Article 14 | 7
Solito and Sastre Microglia in Alzheimer’s disease
El Khoury, J., Hickman, S. E., Thomas,
C. A., Cao, L., Silverstein, S. C.,
and Loike, J. D. (1996). Scav-
enger receptor-mediated adhesion
of microglia to beta-amyloid ﬁbrils.
Nature 382, 716–719.
Falsig, J., van Beek, J., Hermann, C.,
and Leist,M. (2008).Molecular basis
for detection of invading pathogens
in the brain. J. Neurosci. Res. 86,
1434–1447.
Fang, F., Lue, L. F.,Yan, S., Xu,H., Luddy,
J. S., Chen, D., Walker, D. G., Stern,
D. M., Yan, S., Schmidt, A. M., Chen,
J. X., and Yan, S. S. (2010). RAGE-
dependent signaling in microglia
contributes to neuroinﬂammation,
Abeta accumulation, and impaired
learning/memory in a mouse model
of Alzheimer’s disease. FASEB J. 24,
1043–1055.
Farfara, D., Trudler, D., Segev-Amzaleg,
N., Galron, R., Stein, R., and Frenkel,
D. (2011). γ-Secretase component
presenilin is important for microglia
β-amyloid clearance. Ann. Neurol.
69, 170–180.
Farina, C., Aloisi, F., and Meinl, E.
(2007). Astrocytes are active players
in cerebral innate immunity. Trends
Immunol. 28, 138–145.
Fetler, L., and Amigorena, S. (2005).
Neuroscience. Brain under surveil-
lance: the microglia patrol. Science
309, 392–393.
Frautschy, S. A., Yang, F., Irrizarry, M.,
Hyman, B., Saido, T. C., Hsiao, K.,
and Cole, G. M. (1998). Microglial
response to amyloid plaques in
APPsw transgenic mice. Am. J.
Pathol. 152, 307–317.
Fuhrmann, M., Bittner, T., Jung, C.
K., Burgold, S., Page, R. M., Mit-
teregger, G., Haass, C., Laferla, F.
M., Kretzschmar, H., and Herms,
J. (2010). Microglial Cx3cr1
knockout prevents neuron loss in
a mouse model of Alzheimer’s
disease. Nat. Neurosci. 13,
411–413.
Gao,H. M., and Hong, J. S. (2008). Why
neurodegenerative diseases are pro-
gressive: uncontrolled inﬂammation
drives disease progression. Trends
Immunol. 29, 357–365.
Gao, H. M., Kotzbauer, P. T., Uryu,
K., Leight, S., Trojanowski, J. Q.,
and Lee,V. M. (2008). Neuroinﬂam-
mation and oxidation/nitration of
alpha-synuclein linked to dopamin-
ergic neurodegeneration. J.Neurosci.
28, 7687–7698.
Gelinas, D. S., DaSilva, K., Fenili, D.,
St George-Hyslop, P., and McLau-
rin, J. (2004). Immunotherapy for
Alzheimer’s disease. Proc. Natl.
Acad. Sci. U.S.A. 101(Suppl. 2),
14657–14662.
Godbout, J. P., Chen, J., Abraham, J.,
Richwine, A. F., Berg, B. M., Kel-
ley, K. W., and Johnson, R. W.
(2005). Exaggerated neuroinﬂam-
mation and sickness behavior in
agedmice following activation of the
peripheral innate immune system.
FASEB J. 19, 1329–1331.
Grathwohl, S. A., Kälin, R. E., Bol-
mont, T., Prokop, S., Winkelmann,
G., Kaeser, S. A., Odenthal, J., Radde,
R., Eldh, T., Gandy, S., Aguzzi, A.,
Staufenbiel, M., Mathews, P. M.,
Wolburg, H., Heppner, F. L., and
Jucker, M. (2009). Formation and
maintenance of Alzheimer’s disease
beta-amyloid plaques in the absence
of microglia. Nat. Neurosci. 12,
1361–1363.
Grifﬁn, W. S., Stanley, L. C., Ling, C.,
White, L., MacLeod, V., Perrot, L.
J., White, C. L. III, and Araoz, C.
(1989). Brain interleukin 1 and S-
100 immunoreactivity are elevated
in down syndrome and Alzheimer
disease. Proc. Natl. Acad. Sci. U.S.A.
86, 7611–7615.
Hafer-Macko, C. E., Dyck, P. J., and
Koski, C. L. (2000). Complement
activation in acquired and heredi-
tary amyloid neuropathy. J. Peripher.
Nerv. Syst. 5, 131–139.
Heneka, M. T., Sastre, M., Dumitrescu-
Ozimek, L., Dewachter, I., Walter, J.,
Klockgether, T., and Van Leuven, F.
(2005a). Focal glial activation coin-
cides with increased BACE1 activa-
tion and precedes amyloid plaque
deposition in APP(V717I) trans-
genic mice. J. Neuroinﬂammation 2,
22.
Heneka, M. T., Sastre, M., Dumitrescu-
Ozimek, L., Kreutz,A.,Dewachter, I.,
Kuiperi,C.,Klockgether,T.,VanLeu-
ven, F., and Landreth, G. (2005b).
The PPARγ agonist pioglitazone
reduces inﬂammation and Aβ1-42
levels in APPV717I transgenic mice.
Brain 128, 1442–1453.
Heurtaux, T., Michelucci, A., Losci-
uto, S., Gallotti, C., Felten, P., Dor-
ban, G., Grandbarbe, L., Morga,
E., and Heuschling, P. (2010).
Microglial activation depends on
beta-amyloid conformation: role of
the formylpeptide receptor 2. J. Neu-
rochem. 114, 576–586.
Hickman, S. E., Allison, E. K., and
El Khoury, J. (2008). Microglial
dysfunction and defective beta-
amyloid clearance pathways in aging
Alzheimer’s diseasemice. J. Neurosci.
28, 8354–8360.
Husemann, J., Loike, J. D., Anankov,
R., Febbraio, M., and Silverstein, S.
C. (2002). Scavenger receptors in
neurobiology and neuropathology:
their role on microglia and other
cells of the nervous system. Glia 40,
195–205.
Iribarren, P., Zhou, Y., Hu, J., Le,
Y., and Wang, J. M. (2005). Role
of formyl peptide receptor-like
1 (FPRL1/FPR2) in mononuclear
phagocyte responses in Alzheimer
disease. Immunol. Res. 31, 165–176.
Jaworski, T., Lechat, B., Demedts, D.,
Gielis, L., Devijver, H., Borghgraef,
P., Duimel, H., Verheyen, F., Kügler,
S., and Van Leuven, F. (2011). Den-
dritic degeneration, neurovascular
defects, and inﬂammation precede
neuronal loss in a mouse model
for tau-mediated neurodegenera-
tion. Am. J. Pathol. 179, 2001–2015.
Jimenez, S., Baglietto-Vargas, D.,
Caballero, C., Moreno-Gonzalez, I.,
Torres,M., Sanchez-Varo, R., Ruano,
D., Vizuete, M., Gutierrez, A., and
Vitorica, J. (2008). Inﬂammatory
response in the hippocampus of
PS1M146L/APP751SL mouse model of
Alzheimer’s disease: age-dependent
switch in the microglial pheno-
type from alternative to classic. J.
Neurosci. 28, 11650–11661.
Kamboh, M. I., Sanghera, D. K., Fer-
rell, R. E., and DeKosky, S. T. (1995).
APOE∗4-associatedAlzheimer’s dis-
ease risk is modiﬁed by alpha
1-antichymotrypsin polymorphism.
Nat. Genet. 10, 486–488.
Keene, C. D., Cudaback, E., Li, X.,
Montine, K. S., and Montine, T. J.
(2011). Apolipoprotein E isoforms
and regulation of the innate immune
response in brain of patients with
Alzheimer’s disease. Curr. Opin.
Neurobiol. 21, 920–928.
Knapp, M., and Prince, M. (2007).
Dementia UK the Full Report. Lon-
don: Alzheimer’s Society.
Koﬂer, J., and Wiley, C. A. (2011).
Microglia: key innate immune cells
of the brain. Toxicol. Pathol. 39,
103–114.
Kreutzberg, G. W. (1996). Microglia: a
sensor for pathological events in the
CNS. Trends Neurosci. 19, 312–318.
Le,Y.,Gong,W.,Tiffany,H. L.,Tumanov,
A., Nedospasov, S., Shen, W., Dun-
lop, N. M., Gao, J. L., Murphy, P. M.,
Oppenheim, J. J., and Wang, J. M.
(2001). Amyloid (beta)42 activates a
G-protein-coupled chemoattractant
receptor, FPR-like-1. J. Neurosci. 21,
RC123.
Le, Y., Murphy, P. M., and Wang, J.
M. (2002). Formyl-peptide recep-
tors revisited. Trends Immunol. 23,
541–548.
Lehmann, J. M., Lenhard, J. M.,
Oliver, B. B., Ringold, G. M., and
Kliewer, S. A. (1997). Peroxisome
proliferator-activated receptors α
and γ are activated by indomethacin
and other non-steroidal anti-
inﬂammatory drugs. J. Biol. Chem.
272, 3406–3410.
Lehnardt, S. (2010). Innate immunity
and neuroinﬂammation in the CNS:
the role of microglia in Toll-like
receptor-mediated neuronal injury.
Glia 58, 253–263.
Lehnardt, S., Massillon, L., Follett, P.,
Jensen, F. E., Ratan, R., Rosenberg,
P. A., Volpe, J. J., and Vartanian, T.
(2003). Activation of innate immu-
nity in the CNS triggers neurode-
generation through aToll-like recep-
tor 4-dependent pathway. Proc. Natl.
Acad. Sci. U.S.A. 100, 8514–8519.
Lim, G. P., Yang, F., Chu, T., Chen, P.,
Beech, W., Teter, B., Tran, T., Ubeda,
O., Ashe, K. H., Frautschy, S. A.,
and Cole, G. M. (2000). Ibupro-
fen suppresses plaque pathology and
inﬂammation in a mouse model for
Alzheimer’s disease. J. Neurosci. 20,
5709–5714.
Liu, B., and Hong, J.-S. (2003).
Role of microglia in inﬂammation-
mediated neurodegenerative dis-
eases: mechanisms and strategies for
therapeutic intervention. J. Pharma-
col. Exp. Ther. 304, 1–7.
Lleo,A.,Galea, E., and Sastre,M. (2007).
Molecular targets of non-steroidal
anti-inﬂammatory drugs in neu-
rodegenerative diseases. Cell. Mol.
Life Sci. 64, 1403–1418.
Lue, L. F., Kuo, Y. M., Beach, T., and
Walker, D. G. (2010). Microglia acti-
vation and anti-inﬂammatory reg-
ulation in Alzheimer’s disease. Mol.
Neurobiol. 41, 115–128.
Lue, L. F., Walker, D. G., Brachova, L.,
Beach, T. G., Rogers, J., Schmidt, A.
M., Stern, D. M., and Yan, S. D.
(2001). Involvement of microglial
receptor for advanced glycation end-
products (RAGE) inAlzheimer’s dis-
ease: identiﬁcation of a cellular acti-
vation mechanism. Exp. Neurol. 171,
29–45.
Mackenzie, I. R., and Muñoz, D.
G. (1998). Nonsteroidal anti-
inﬂammatory drug use and
Alzheimer-type pathology in aging.
Neurology 50, 986–990.
Maeda, J., Zhang, M. R., Okauchi, T., Ji,
B., Ono, M., Hattori, S., Kumata, K.,
Iwata, N., Saido, T. C., Trojanowski,
J. Q., Lee, V. M., Staufenbiel, M.,
Tomiyama, T., Mori, H., Fukumura,
T.,Suhara,T andHiguchi,M. (2011).
In vivo positron emission tomo-
graphic imaging of glial responses to
amyloid-beta and tau pathologies in
mousemodels ofAlzheimer’s disease
and related disorders. J. Neurosci. 31,
4720–4730.
Mandrekar, S., Jiang, Q., Lee, C.
Y., Koenigsknecht-Talboo, J.,
Frontiers in Pharmacology | Neuropharmacology February 2012 | Volume 3 | Article 14 | 8
Solito and Sastre Microglia in Alzheimer’s disease
Holtzman, D. M., and Landreth, G.
E. (2009). Microglia mediate the
clearance of soluble Abeta through
ﬂuid phase macropinocytosis. J.
Neurosci. 29, 4252–4262.
Maragakis, N. J., and Rothstein, J.
D. (2006). Mechanisms of disease:
astrocytes in neurodegenerative dis-
ease. Nat. Clin. Pract. Neurol. 2,
679–689.
Matsuoka, Y., Picciano, M., Malester, B.,
LaFrancois, J., Zehr, C., Daeschner,
J. M., Olschowka, J. A., Fonseca, M.
I., O’Banion, M. K., Tenner, A. J.,
Lemer, C. A., and Duff, K. (2001).
Inﬂammatory responses to amyloi-
dosis in a transgenic mouse model
of Alzheimer’s disease. Am. J. Pathol.
158, 1345–1354.
McArthur, S., Cristante, E., Paterno, M.,
Christian, H., Roncaroli, F., Gillies,
G. E., and Solito, E. (2010). Annexin
A1: a central player in the anti-
inﬂammatory and neuroprotective
role of microglia. J. Immunol. 185,
6317–6328.
McColl, B.W.,Rothwell,N. J., andAllan,
S.M. (2007). Systemic inﬂammatory
stimulus potentiates the acute phase
and CXC chemokine responses to
experimental stroke and exacerbates
brain damage via interleukin-1- and
neutrophil-dependent mechanisms.
J. Neurosci. 27, 4403–4412.
McCusker, S. M., Curran,M. D., Dynan,
K. B., McCullagh, C. D., Urquhart,
D. D., Middleton, D., Patterson, C.
C., McIlroy, S. P., and Passmore, A.
P. (2001). Association between poly-
morphism in regulatory region of
gene encoding tumour necrosis fac-
tor alpha and risk of Alzheimer’s dis-
ease and vascular dementia: a case-
control study. Lancet 357, 436–439.
McGeer, P. L., and McGeer, E. G.
(1998). Mechanisms of cell death in
Alzheimer disease – immunopathol-
ogy. J. Neural Transm. Suppl. 54,
159–166.
Miyake,K. (2007). Innate immune sens-
ing of pathogens and danger signals
by cell surface toll-like receptors.
Semin. Immunol. 19, 3–10.
Mrak, R. E., and Grifﬁn,W. S. T. (2005).
Glia and their cytokines in progres-
sion of neurodegeneration. Neuro-
biol. Aging 26, 349–354.
Napoli, I., and Neumann, H. (2009).
Microglial clearance function in
health and disease.Neuroscience 158,
1030–1038.
Neher, J. J., Neniskyte, U., Zhao, J.
W., Bal-Price, A., Tolkovsky, A. M.,
and Brown, G. C. (2011). Inhibi-
tion of microglial phagocytosis is
sufﬁcient to prevent inﬂammatory
neuronal death. J. Immunol. 186,
4973–4983.
Neumann, H., Kotter, M. R., and
Franklin, R. J. (2009). Debris clear-
ance by microglia: an essential link
between degeneration and regenera-
tion. Brain 132, 288–295.
Nguyen, M. D., D’Aigle, T., Gowing, G.,
Julien, J. P., and Rivest, S. (2004).
Exacerbation of motor neuron dis-
ease by chronic stimulation of innate
immunity in a mouse model of amy-
otrophic lateral sclerosis. J. Neurosci.
24, 1340–1349.
Nicoll, J. A., Mrak, R. E., Graham, D.
I., Stewart, J., Wilcock, G., Mac-
Gowan, S., Esiri, M. M., Murray, L.
S., Dewar, D., Love, S., Moss, T., and
Grifﬁn, W. S. (2000). Association of
interleukin-1 gene polymorphisms
with Alzheimer’s disease. Ann. Neu-
rol. 47, 365–368.
Nimmerjahn, A., Kirchhoff, F., and
Helmchen, F. (2005). Resting
microglial cells are highly dynamic
surveillants of brain parenchyma
in vivo. Science 308, 1314–1318.
Njie, E. G., Boelen, E., Stassen, F. R.,
Steinbusch, H. W., Borchelt, D. R.,
and Streit, W. J. (2012). Ex vivo cul-
tures of microglia from young and
aged rodent brain reveal age-related
changes in microglial function. Neu-
robiol. Aging 33, 195.e1–195.e12.
Okello, A., Edison, P., Archer, H. A.,
Turkheimer, F. E., Kennedy, J., Bul-
lock, R., Walker, Z., Kennedy, A.,
Fox, N., Rossor, M., and Brooks, D.
J. (2009). Microglial activation and
amyloiddeposition inmild cognitive
impairment: a PET study. Neurology
72, 56–62.
Ouchi, Y., Yoshikawa, E., Sekine,
Y., Futatsubashi, M., Kanno, T.,
Ogusu, T., and Torizuka, T. (2005).
Microglial activation and dopamine
terminal loss in early Parkinson’s
disease. Ann. Neurol. 57, 168–175.
Pan, X. D., Zhu, Y. G., Lin, N.,
Zhang, J., Ye, Q. Y., Huang, H. P.,
and Chen, X. C. (2011). Microglial
phagocytosis induced by ﬁbril-
lar beta-amyloid is attenuated by
oligomeric beta-amyloid: implica-
tions for Alzheimer’s disease. Mol.
Neurodegener. 6, 45.
Pancer, Z., and Cooper, M. D. (2006).
The evolution of adaptive immunity.
Annu. Rev. Immunol. 24, 497–518.
Paresce, D. M., Ghosh, R. N., and
Maxﬁeld, F. R. (1996). Microglial
cells internalize aggregates of the
Alzheimer’s disease amyloid beta-
protein via a scavenger receptor.
Neuron 17, 553–565.
Permanne, B., Adessi, C., Saborio, G.
P., Fraga, S., Frossard, M. J., Van
Dorpe, J., Dewachter, I., Banks, W.
A., Van Leuven, F., and Soto, C.
(2002). Reduction of amyloid load
and cerebral damage in a transgenic
mouse model of Alzheimer’s disease
by treatment with a b-sheet breaker
peptide. FASEB J. 16, 860–862.
Perretti, M., and D’Acquisto, F. (2009).
Annexin A1 and glucocorticoids as
effectors of the resolution of inﬂam-
mation.Nat. Rev. Immunol. 9,62–70.
Perry, R. T., Collins, J. S., Wiener, H.,
Acton, R., and Go, R. C. P. (2001).
The role of TNF and its receptors
in Alzheimer’s disease. Neurobiol.
Aging 22, 873–883.
Perry, V. H. (2004). The inﬂuence of
systemic inﬂammation on inﬂam-
mation in the brain: implications for
chronic neurodegenerative disease.
Brain Behav. Immun. 18, 407–413.
Perry,V.H., andAndersson,P. B. (1992).
The inﬂammatory response in the
CNS. Neuropathol. Appl. Neurobiol.
18, 454–459.
Perry, V. H., Anthony, D. C., Bell, M.
D., Lawson, L. J., Reid, D. M., and
Gordon, S. (1996). Microglia activa-
tion and inﬂammation in the CNS.
J. Neurochem. 66, S70.
Perry, V. H., Cunningham, C., and
Holmes, C. (2007). Systemic infec-
tions and inﬂammation affect
chronic neurodegeneration. Nat.
Rev. Immunol. 7, 161–167.
Perry,V. H.,Matyszak,M. K., and Fearn,
S. (1993). Altered antigen expression
of microglia in the aged rodent CNS.
Glia 7, 60–67.
Perry, V. H., Nicoll, J. A., and Holmes,
C. (2010). Microglia in neurodegen-
erative disease. Nat. Rev. Neurol. 6,
193–201.
Polazzi, E., and Monti, B. (2010).
Microglia and neuroprotection:
from in vitro studies to therapeutic
applications. Prog. Neurobiol. 92,
293–315.
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrel-
lis, K., Zhang, J., Podlisny, M. B.,
Rosner, M. R., Safavi, A., Hersh, L.
B., and Selkoe, D. J. (1998). Insulin-
degrading enzyme regulates extra-
cellular levels of amyloid b-protein
by degradation. J. Biol. Chem. 273,
32730–32738.
Qiu,W. Q., Ye, Z., Kholodenko, D., Seu-
bert, P., and Selkoe, D. J. (1997).
Degradation of amyloid b-protein
by a metalloprotease secreted by
microglia and other neural and non-
neural cells. J. Biol. Chem. 272,
6641–6646.
Ransohoff, R. M., and Perry, V.
H. (2009). Microglial physiol-
ogy: unique stimuli, specialized
responses. Annu. Rev. Immunol. 27,
119–145.
Reed-Geaghan, E. G., Savage, J. C., Hise,
A. G., and Landreth, G. E. (2009).
CD14 and toll-like receptors 2 and
4 are required for ﬁbrillar A{beta}-
stimulated microglial activation. J.
Neurosci. 29, 11982–11992.
Richard, K. L., Filali, M., Préfontaine, P.,
and Rivest, S. (2008). Toll-like recep-
tor 2 acts as a natural innate immune
receptor to clear amyloid beta 1-42
and delay the cognitive decline in a
mouse model of Alzheimer’s disease.
J. Neurosci. 28, 5784–5793.
Rivest, S. (2003). Molecular insights on
the cerebral innate immune system.
Brain Behav. Immun. 17, 13–19.
Rivest, S. (2009). Regulation of innate
immune responses in the brain. Nat.
Rev. Immunol. 9, 429–439.
Roberts, J. C., Friel, S. L., Roman, S.,
Perren, M., Harper, A., Davis, J. B.,
Richardson, J. C., Virley, D., and
Medhurst, A. D. (2009). Autoradi-
ographical imaging of PPARgamma
agonist effects on PBR/TSPO bind-
ing in TASTPM mice. Exp. Neurol.
216, 459–470.
Rogers, J., Mastroeni, D., Leonard, B.,
Joyce, J., and Grover,A. (2007). Neu-
roinﬂammation in Alzheimer’s dis-
ease and Parkinson’s disease: are
microglia pathogenic in either disor-
der? Int. Rev. Neurobiol. 82, 235–246.
Salminen, A., Ojala, J., Kauppinen,
A., Kaarniranta, K., and Suuro-
nen, T. (2009). Inﬂammation in
Alzheimer’s disease: amyloid-beta
oligomers trigger innate immu-
nity defence via pattern recogni-
tion receptors. Prog. Neurobiol. 87,
181–194.
Sastre, M., and Gentleman, S. M.
(2010). NSAIDs: how they
work and their prospects as
therapeutics in Alzheimer’s dis-
ease. Front. Aging Neurosci. 2:20.
doi:10.3389/fnagi.2010.00020
Sastre, M., Klockgether, T., and
Heneka, M. T. (2006a). Contri-
bution of inﬂammatory processes
to Alzheimer’s disease: molecular
mechanisms. Int. J. Dev. Neurosci.
24, 167–176.
Sastre, M., Roßner, S., Bogdanovic,
N., Rosen, E., Dewachter, I., Thal,
D., Evert, B., Klockgether, T.,
van Leuven, F., and Heneka, M.
T. (2006b). Non-steroidal anti-
inﬂammatory drugs repress beta-
secretase gene promoter activity by
the activation of PPARgamma. Proc.
Natl. Acad. Sci. U.S.A. 103, 443–448.
Sastre,M., Richardson, J., Gentleman, S.
M., and Brooks, D. (2011). Inﬂam-
matory risk factors and patholo-
gies associated with Alzheimer’s
disease. Curr. Alzheimer Res. 8,
132–141.
Sastre, M., Walter, J., and Gentleman,
S. M. (2008). Interactions between
APP secretases and inﬂammatory
www.frontiersin.org February 2012 | Volume 3 | Article 14 | 9
Solito and Sastre Microglia in Alzheimer’s disease
mediators. J. Neuroinﬂammation
5, 25.
Schmidt, A. M.,Yan, S. D.,Yan, S. F., and
Stern,D. M. (2001). The multiligand
receptor RAGE as a progression fac-
tor amplifying immune and inﬂam-
matory responses. J. Clin. Invest. 108,
949–955.
Schwartz, M., and Shechter, R. (2010).
Systemic inﬂammatory cells ﬁght off
neurodegenerative disease. Nat. Rev.
Neurol. 6, 405–410.
Shen, Y., and Meri, S. (2003). Yin and
Yang: complement activation and
regulation in Alzheimer’s disease.
Prog. Neurobiol. 70, 463–472.
Shi, J. Q., Shen, W., Chen, J., Wang, B.
R., Zhong, L. L., Zhu, Y. W., Zhu, H.
Q., Zhang, Q. Q., Zhang, Y. D., and
Xu, J. (2011). Anti-TNF-α reduces
amyloid plaques and tau phospho-
rylation and inducesCD11c-positive
dendritic-like cell in the APP/PS1
transgenic mouse brains. Brain Res.
1368, 239–247.
Sierra, A., Gottfried-Blackmore, A.
C., McEwen, B. S., and Bulloch,
K. (2007). Microglia derived from
aging mice exhibit an altered inﬂam-
matory proﬁle. Glia 55, 412–424.
Solito, E., McArthur, S., Christian,
H., Gavins, F., Buckingham, J. C.,
and Gillies, G. E. (2008). Annexin
A1 in the brain – undiscovered
roles? Trends Pharmacol. Sci. 29,
135–142.
Streit, W., Braak, H., Xue, Q. S., and
Bechmann, I. (2009). Dystrophic
(senescent) rather than activated
microglial cells are associated with
tau pathology and likely precede
neurodegeneration in Alzheimer’s
disease. Acta Neuropathol. 118,
475–485.
Streit, W. J., Miller, K. R., Lopes, K.
O., and Njie, E. (2008). Microglial
degeneration in the aging brain –
bad news for neurons? Front. Biosci.
13, 3423–3438.
Streit, W. J., Sammons, N. W., Kuhns,
A. J., and Sparks, D. L. (2004).
Dystrophic microglia in the aging
human brain. Glia 45, 208–212.
Sy, M., Kitazawa, M., Medeiros, R.,
Whitman, L., Cheng, D., Lane, T. E.,
and Laferla, F. M. (2011). Inﬂam-
mation induced by infection poten-
tiates tau pathological features in
transgenic mice. Am. J. Pathol. 178,
2811–2822.
Tahara,K., Kim,H. D., Jin, J. J.,Maxwell,
J. A., Li, L., and Fukuchi, K. (2006).
Role of toll-like receptor signalling
in Abeta uptake and clearance. Brain
129, 3006–3019.
Walter, S., Letiembre, M., Liu, Y.,
Heine, H., Penke, B., Hao, W.,
Bode, B., Manietta, N., Walter,
J., Schulz-Schuffer, W., and Fass-
bender, K. (2007). Role of the
toll-like receptor 4 in neuroin-
ﬂammation in Alzheimer’s dis-
ease. Cell. Physiol. Biochem. 20,
947–956.
Weiner, H. L., and Selkoe, D. J. (2002).
Inﬂammation and therapeutic vac-
cination in CNS diseases. Nature
420, 879–884.
Weller, C., Oxlade, N., Dobbs, S.
M., Dobbs, R. J., Charlett, A.,
and Bjarnason, I. T. (2005). Role
of inﬂammation in gastrointesti-
nal tract in aetiology and patho-
genesis of idiopathic parkinsonism.
FEMS Immunol. Med. Microbiol. 44,
129–135.
Willson, T. M., Brown, P. J., Sternbach,
D. D., and Henke, B. R. (2000). The
PPARs: from orphan receptors to
drug discovery. J. Med. Chem. 43,
527–550.
Wyss-Coray, T. (2006). Inﬂammation
in Alzheimer disease: driving force,
bystander or beneﬁcial response?
Nat. Med. 12, 1005–1015.
Wyss-Coray, T., Loike, J. D., Brionne,
T. C., Lu, E., Anankov, R., Yan,
F., Silverstein, S. C., Husemann,
J. (2003). Adult mouse astrocytes
degrade amyloid-beta in vitro and
in situ. Nat. Med. 9, 453–457.
Xie, Z., Morgan, T. E., Rozovsky, I.,
and Finch, C. E. (2003). Aging and
glial responses to lipopolysaccharide
in vitro: greater induction of IL-
1 and IL-6, but smaller induction
of neurotoxicity. Exp. Neurol. 182,
135–141.
Yan, S. D., Chen, X., Fu, J., Chen,
M., Zhu, H., Roher, A., Slattery, T.,
Zhao, L., Nagashima, M., Morser, J.,
Migheli, A., Nawroth, P., Stern, D.,
and Schmidt, A. M. (1996). RAGE
and amyloid-beta peptide neurotox-
icity in Alzheimer’s disease. Nature
382, 685–691.
Yang, M. S., Ji, K. A., Jeon, S. B.,
Jin, B. K., Kim, S. U., Jou, I.,
and Joe, E. (2006). Interleukin-13
enhances cyclooxygenase-2 expres-
sion in activated rat brain microglia:
implications for death of acti-
vated microglia. J. Immunol. 177,
1323–1329.
Ye, S. M., and Johnson, R. W.
(1999). Increased interleukin-6
expression by microglia from brain
of aged mice. J. Neuroimmunol. 93,
139–148.
Yong,V.W., andRivest, S. (2009). Taking
advantage of the systemic immune
system to cure braindiseases.Neuron
64, 55–60.
Yoshiyama, Y., Higuchi, M., Zhang, B.,
Huang, S. M., Iwata, N., Saido,
T. C., Maeda, J., Suhara, T., Tro-
janowski, J.Q., andLee,V.M. (2007).
Synapse loss and microglial acti-
vation precede tangles in a P301S
tauopathy mouse model. Neuron 53,
337–351.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 14 November 2011; accepted:
21 January 2012; published online: 10
February 2012.
Citation: Solito E and Sastre M (2012)
Microglia function in Alzheimer’s dis-
ease. Front. Pharmacol. 3:14. doi:
10.3389/fphar.2012.00014
This article was submitted to Frontiers
in Neuropharmacology, a specialty of
Frontiers in Pharmacology.
Copyright © 2012 Solito and Sastre. This
is an open-access article distributed under
the terms of the Creative Commons Attri-
bution Non Commercial License, which
permits non-commercial use, distribu-
tion, and reproduction in other forums,
provided the original authors and source
are credited.
Frontiers in Pharmacology | Neuropharmacology February 2012 | Volume 3 | Article 14 | 10
